Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-resistant Prostate Cancer
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer.
- Trial name
- NCT05125016
- Testing
- REGN4336, REGN5678
- Where
- 14 sites in United States
- Volunteers
- 228 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
This randomized pilot study will be conducted in men with metastatic castration resistant prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide.
- Trial name
- NCT02130947
- Testing
- Exercise
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT04951492
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Prostate Cancer
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- SHIP (NCT02146833)
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Karyopharm Therapeutics Inc
Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
JUR-003 in Adult Patients With Metastatic Prostate Cancer
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer.
- Conditions
- Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07824349
- Testing
- JUR-003
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Juri Biosciences, Inc.
Prostate Cancer
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
This is a Phase Ib, open-label, multi-centre study to determine the safety, tolerability and pharmacokinetics (PK) of capivasertib when given in combination with novel agents (enzalutamide or abiraterone) to inform the selection…
- Trial name
- NCT04087174
- Testing
- Capivasertib, Enzalutamide, Abiraterone
- Where
- 6 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Metastatic Castration Resistant Prostate Cancer
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study.
- Trial name
- NCT06866795
- Testing
- GT-220F capsule
- Volunteers
- 42 people
- Sponsor
- Geode Therapeutics Inc.
Prostatic Neoplasms, Castration-Resistant
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to find and evaluate the recommended Phase 2 dose (RP2D) of JNJ-64041809, a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules…
- Trial name
- NCT02625857
- Testing
- JNJ-64041809 (Cohort 1A and 1B), JNJ-64041809 (Cohort 2A and 2B)
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide…
- Trial name
- IMbassador250 (NCT03016312)
- Testing
- Atezolizumab, Enzalutamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 759 people
- Sponsor
- Hoffmann-La Roche
Metastatic Prostate Cancer
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
- Trial name
- PROSPECTOR (NCT07590934)
- Testing
- AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Prostate Cancer
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
- Trial name
- NCT06826768
- Testing
- REGN5678, Cemiplimab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment.
- Conditions
- Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT04781374
- Testing
- Neratinib
- Where
- 3 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Non-metastatic Castration-resistant Prostate Cancer
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that…
- Trial name
- NCT05348876
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 25 sites in India
- Volunteers
- 50 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT02861573
- Testing
- Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer Metastatic, Prostate Cancer
Castrate Resistant Prostate Cancer Enhertu Therapy
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer, CRPC
- Trial name
- CaRPET (NCT06610825)
- Testing
- Enhertu
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington D.C. Veterans Affairs Medical Center
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene